Publications (16) Publications in which a researcher has participated

2011

  1. BiovaxID®: A customized idiotype vaccine for the treatment of B-cell lymphoma

    Expert Review of Vaccines, Vol. 10, Núm. 12, pp. 1661-1669

  2. Carcinoma-derived Interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation

    PLoS ONE, Vol. 6, Núm. 3

  3. Defining the critical hurdles in cancer immunotherapy

    Journal of Translational Medicine

  4. Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes

    PLoS ONE, Vol. 6, Núm. 12

  5. Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens

    Leukemia Research, Vol. 35, Núm. 10, pp. 1412-1415

  6. Direct effects of type I interferons on cells of the immune system

    Clinical Cancer Research, Vol. 17, Núm. 9, pp. 2619-2627

  7. IV Latin American consensus on the treatment of lymphedema

    Journal Phlebology and Lymphology, Vol. 4, Núm. 1, pp. 13-16

  8. Idiotype vaccines for lymphoma therapy

    Expert Review of Vaccines, Vol. 10, Núm. 6, pp. 801-809

  9. Inmunología y nuestra identidad como sociedad científica

    Inmunologia

  10. International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010

    Cancer Immunology, Immunotherapy

  11. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy

    International Journal of Cancer, Vol. 128, Núm. 1, pp. 105-118

  12. New trends in immunotherapy

    Inmunologia

  13. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients

    Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142

  14. Simb16: Modeling induced immune system response against B16-melanoma

    PLoS ONE, Vol. 6, Núm. 10

  15. Stem cell transplant and idiotypic vaccination for B-cell malignancies

    Current Topics in Medicinal Chemistry, Vol. 11, Núm. 13, pp. 1653-1660

  16. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

    International Journal of Cancer, Vol. 129, Núm. 2, pp. 374-386